✦ LIBER ✦

Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products

✍ Scribed by Weissinger, Judi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nonclinical strategy considerations for

✍ Vargas, Hugo M; Amouzadeh, Hamid R; Engwall, Michael J 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 329 KB

Toxicological considerations for protein

✍ Sjoblad, Roy D.; McClintock, J.Thomas; Engler, Reto 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 590 KB

Nonclinical Development of Novel Biologi

✍ Wolf, Jayanthi J. 📂 Article 📅 2013 🏛 Elsevier ⚖ 254 KB

Evaluating SGLT2 inhibitors for type 2 d

✍ Scheen, André J 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 427 KB

Nonclinical Development of Novel Biologi

✍ Mounho-Zamora, Barbara 📂 Article 📅 2013 🏛 Elsevier ⚖ 486 KB

Emergency Department Evaluation and Trea

✍ Cyrus Rangan 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 117 KB